Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


10.06.2024

1 AJR Am J Roentgenol
5 Anticancer Res
2 Arch Bronconeumol
6 BMC Cancer
1 Br J Cancer
3 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
1 Cancer Res
3 Cancer Sci
2 Clin Cancer Res
1 Clin Lung Cancer
1 Eur J Cancer
3 Eur Respir J
1 Int J Cancer
1 J Cancer Res Clin Oncol
5 J Clin Oncol
1 J Natl Cancer Inst
1 J Nucl Med
1 Lancet Oncol
13 Lung Cancer
1 N Engl J Med
1 Oncologist
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. HAMMER MM
    Editorial Comment: The Prognostic Importance of a Ground-Glass Component in Lung Cancer.
    AJR Am J Roentgenol. 2024 Jun 5. doi: 10.2214/AJR.24.31518.
    PubMed        


    Anticancer Res

  2. SWITLIK W, Wyzewski Z, Gregorczyk-Zboroch K, Gietler M, et al
    Deciphering the Role of miR-30a-5p and DLGAP1 Gene in Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:2445-2451.
    PubMed         Abstract available

  3. ANO S, Kikuchi N, Okauchi S, Numata T, et al
    Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer.
    Anticancer Res. 2024;44:2725-2730.
    PubMed         Abstract available

  4. ENDO K, Tanaka H, Matsuo H, Onoda T, et al
    Adverse Event Profile of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Combination Therapy Based on JADER.
    Anticancer Res. 2024;44:2653-2660.
    PubMed         Abstract available

  5. SEO HR, Kim HJ, Ryu H, Song JY, et al
    Ionizing Radiation-treated NRF2-deficient Cancer Cells Promote Type I Interferon Signaling in Immune Cells.
    Anticancer Res. 2024;44:2577-2585.
    PubMed         Abstract available

  6. PARK JS, Park HY, Choi Y
    Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
    Anticancer Res. 2024;44:2681-2687.
    PubMed         Abstract available


    Arch Bronconeumol

  7. WANG K, Yi H, Wang Y, Jin D, et al
    Proteome-Wide Multicenter Mendelian Randomization Analysis to Identify Novel Therapeutic Targets for Lung Cancer.
    Arch Bronconeumol. 2024 May 16:S0300-2896(24)00168.
    PubMed         Abstract available

  8. TZOUVELEKIS A, Tsiri P, Sampsonas F
    Challenges in the Management of Lung Cancer in ILD.
    Arch Bronconeumol. 2024 May 16:S0300-2896(24)00174.
    PubMed        


    BMC Cancer

  9. ZHAO J, Lu Y, Ren X, Bian T, et al
    Association of the SHOX2 and RASSF1A methylation levels with the pathological evolution of early-stage lung adenocarcinoma.
    BMC Cancer. 2024;24:687.
    PubMed         Abstract available

  10. BIYU H, Mengshan L, Yuxin H, Ming Z, et al
    A miRNA-disease association prediction model based on tree-path global feature extraction and fully connected artificial neural network with multi-head self-attention mechanism.
    BMC Cancer. 2024;24:683.
    PubMed         Abstract available

  11. LIU Y, Huang J, Chen JC, Chen W, et al
    Predicting treatment response in multicenter non-small cell lung cancer patients based on federated learning.
    BMC Cancer. 2024;24:688.
    PubMed         Abstract available

  12. HUI W, Li W, Song R, Xin Y, et al
    Time-dependent efficacy analysis of first-line immunotherapies for advanced non-small cell lung cancer.
    BMC Cancer. 2024;24:684.
    PubMed         Abstract available

  13. SONG W, Li Y, Yao Y, Sun S, et al
    Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for lung cancer.
    BMC Cancer. 2024;24:680.
    PubMed         Abstract available

  14. YANG L, Jiang Z, Tong J, Li N, et al
    Development and validation of a preoperative CT?based radiomics nomogram to differentiate tuberculosis granulomas from lung adenocarcinomas: an external validation study.
    BMC Cancer. 2024;24:670.
    PubMed         Abstract available


    Br J Cancer

  15. YOSHIMURA A, Horinaka M, Yaoi T, Ono H, et al
    Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.
    Br J Cancer. 2024 May 31. doi: 10.1038/s41416-024-02727.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  16. BEKELE BB, Lian M, Shrestha P, Nabi O, et al
    Racialized economic segregation and treatment and outcomes of small-cell lung cancer.
    Cancer Epidemiol Biomarkers Prev. 2024 Jun 5. doi: 10.1158/1055-9965.EPI-24-0237
    PubMed         Abstract available

  17. PELLINI B, Chaudhuri AA
    Racial Disparities in Early-Stage NSCLC Treatment: A Call for Action.
    Cancer Epidemiol Biomarkers Prev. 2024;33:769-770.
    PubMed         Abstract available

  18. THOMAS AL, Rhee J, Fisher JA, Horner MJ, et al
    Fine Particulate Matter, Noise Pollution, and Greenspace and Prostate Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort.
    Cancer Epidemiol Biomarkers Prev. 2024;33:857-860.
    PubMed         Abstract available


    Cancer Lett

  19. ZHANG L, Xu Y, Cheng Z, Zhao J, et al
    The EGR1/miR-139/NRF2 axis orchestrates radiosensitivity of non-small-cell lung cancer via ferroptosis.
    Cancer Lett. 2024;595:217000.
    PubMed         Abstract available

  20. LIU X, Zheng W, Zhang L, Cao Z, et al
    Corrigendum to "Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer cell proliferation" [Cancer Lett. 586 (2024) 216707/CAN_216707].
    Cancer Lett. 2024 Jun 5:217003. doi: 10.1016/j.canlet.2024.217003.
    PubMed        


    Cancer Res

  21. HERZOG C, Jones A, Evans I, Raut JR, et al
    Cigarette Smoking and E-cigarette Use Induce Shared DNA Methylation Changes Linked to Carcinogenesis.
    Cancer Res. 2024;84:1898-1914.
    PubMed         Abstract available


    Cancer Sci

  22. FUKUDA H, Arai K, Mizuno H, Nishito Y, et al
    Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
    Cancer Sci. 2024;115:1763-1777.
    PubMed         Abstract available

  23. RAUT JR, Bhardwaj M, Schottker B, Holleczek B, et al
    Cancer-specific risk prediction with a serum microRNA signature.
    Cancer Sci. 2024;115:2049-2058.
    PubMed         Abstract available

  24. GUO Y, Kasai Y, Tanaka Y, Ohashi-Kumagai Y, et al
    IGSF3 is a homophilic cell adhesion molecule that drives lung metastasis of melanoma by promoting adhesion to vascular endothelium.
    Cancer Sci. 2024;115:1936-1947.
    PubMed         Abstract available


    Clin Cancer Res

  25. DALAL B, Tada T, Patel DP, Pine SR, et al
    Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Non-smokers and Tobacco Smokers.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0637.
    PubMed         Abstract available

  26. ROLFO CD, Madison RW, Pasquina LW, Brown DW, et al
    Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.
    Clin Cancer Res. 2024;30:2452-2460.
    PubMed         Abstract available


    Clin Lung Cancer

  27. TANVETYANON T, Chen DT, Gray JE
    Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis.
    Clin Lung Cancer. 2024 Apr 30:S1525-7304(24)00078.
    PubMed         Abstract available


    Eur J Cancer

  28. LUKE JJ, Long GV, Robert C, Carlino MS, et al
    Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
    Eur J Cancer. 2024;207:114146.
    PubMed         Abstract available


    Eur Respir J

  29. CAI J, Vonder M, Du Y, Pelgrim GJ, et al
    Who is at risk of lung nodules on low-dose CT in a Western country? A population-based approach.
    Eur Respir J. 2024;63:2301736.
    PubMed         Abstract available

  30. D'AMOURS MF, Wu FTH, Theisen-Lauk O, Chan EK, et al
    Surgically Resectable Non-Small Cell Lung Cancer: A Contemporary Approach.
    Eur Respir J. 2024 Jun 6:2400332. doi: 10.1183/13993003.00332-2024.
    PubMed         Abstract available

  31. SEIJO LM, Zulueta JJ
    The tip of the iceberg: a plethora of lung nodules in the general population.
    Eur Respir J. 2024;63:2400889.
    PubMed        


    Int J Cancer

  32. CHEN C, Zhou X, Gao X, Pan R, et al
    Immune responses and reinfection of SARS-CoV-2 Omicron variant in patients with lung cancer.
    Int J Cancer. 2024 Jun 5. doi: 10.1002/ijc.35038.
    PubMed         Abstract available


    J Cancer Res Clin Oncol

  33. LI Y, Wan Y, Yang X, Chen P, et al
    Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting.
    J Cancer Res Clin Oncol. 2024;150:290.
    PubMed         Abstract available


    J Clin Oncol

  34. YU Y, Miao E, Pike LRG
    Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's Bargain?
    J Clin Oncol. 2024;42:2107-2108.
    PubMed        

  35. LI W, Xiong A, Yang N, Fan H, et al
    Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study.
    J Clin Oncol. 2024 Jun 1:JCO2400731. doi: 10.1200/JCO.24.00731.
    PubMed         Abstract available

  36. PEROL M, Solomon BJ, Goto K, Park K, et al
    CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Jun 3:JCO2400724. doi: 10.1200/JCO.24.00724.
    PubMed         Abstract available

  37. PARK S, Baldry R, Jung HA, Sun JM, et al
    Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    J Clin Oncol. 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708.
    PubMed         Abstract available

  38. PAZ-ARES LG, Juan-Vidal O, Mountzios GS, Felip E, et al
    Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
    J Clin Oncol. 2024 May 31:JCO2400733. doi: 10.1200/JCO.24.00733.
    PubMed         Abstract available


    J Natl Cancer Inst

  39. UPRETY D, Seaton R, Hadid T, Mamdani H, et al
    Racial and socioeconomic disparities in survival among patients with metastatic Non-Small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 3:djae118. doi: 10.1093.
    PubMed         Abstract available


    J Nucl Med

  40. RICH AA, Taunk NK, Mankoff DA, Pantel AR, et al
    [(18)F]Fluoroestradiol Uptake in Irradiated Lung Parenchyma and Draining Nodes.
    J Nucl Med. 2024;65:990-991.
    PubMed        


    Lancet Oncol

  41. CHEN L, Zhu XZ, Zhao SJ, Yang QW, et al
    PD-L1 as a predictive factor for non-small-cell lung cancer prognosis.
    Lancet Oncol. 2024;25:e233.
    PubMed        


    Lung Cancer

  42. KLOTZ LV, Casjens S, Johnen G, Taeger D, et al
    Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients.
    Lung Cancer. 2024;192:107802.
    PubMed         Abstract available

  43. ISHIDOYA M, Makiguchi T, Tanaka H, Miura T, et al
    Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias.
    Lung Cancer. 2024;192:107790.
    PubMed         Abstract available

  44. MARTIN A, Carton M, Thery L, Burnod A, et al
    Palliative care integration and end-of-life care intensity for patients with NSCLC.
    Lung Cancer. 2024;192:107800.
    PubMed         Abstract available

  45. SHAH R, Sun L, Ridge CA
    Image guided lung biopsy.
    Lung Cancer. 2024;192:107803.
    PubMed         Abstract available

  46. CHEN Q, Xia L, Wang J, Zhu S, et al
    EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment.
    Lung Cancer. 2024;192:107815.
    PubMed         Abstract available

  47. SZENTKERESZTY M, Ladanyi A, Galffy G, Tovari J, et al
    Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma.
    Lung Cancer. 2024;192:107824.
    PubMed         Abstract available

  48. SHI M, Pang L, Zhou H, Mo S, et al
    Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
    Lung Cancer. 2024;192:107818.
    PubMed         Abstract available

  49. VORUGANTI MADDALI IS, Cunningham C, McLeod L, Bahig H, et al
    Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study.
    Lung Cancer. 2024;192:107822.
    PubMed         Abstract available

  50. LI M, Zhang Y, Zhou P, Miao Y, et al
    Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor.
    Lung Cancer. 2024;192:107825.
    PubMed         Abstract available

  51. GOTO E, Taki T, Nomura K, Miyakami Y, et al
    Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern.
    Lung Cancer. 2024;192:107830.
    PubMed         Abstract available

  52. BARAMIDZE A, Makharadze T, Gogishvili M, Melkadze T, et al
    Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 >/= 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
    Lung Cancer. 2024;193:107821.
    PubMed         Abstract available

  53. AMARI L, Tomasini P, Dantony E, Rousseau-Bussac G, et al
    Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC
    Lung Cancer. 2024;193:107843.
    PubMed         Abstract available

  54. HUANG L, Petersen RH
    Impact of number of dissected lymph nodes on recurrence and survival following thoracoscopic segmentectomy for clinical stage I non-small cell lung cancer.
    Lung Cancer. 2024;193:107846.
    PubMed         Abstract available


    N Engl J Med

  55. VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al
    Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
    N Engl J Med. 2024;390:2011-2022.
    PubMed        


    Oncologist

  56. NEAL JW, Minichiello K, Brennick R, Huang RSP, et al
    A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
    Oncologist. 2024;29:e843-e847.
    PubMed         Abstract available


    PLoS One

  57. BOUKANSA S, Mouhrach I, El Agy F, El Bardai S, et al
    Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report.
    PLoS One. 2024;19:e0298721.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.